FASN is associated with poor clinical outcomes, presents a universal upregulation, and is involved in the progression, maintenance, and enhancement of the malignant phenotype in most human cancers (prostate, ovarian, breast, endometrial, thyroid, colorectal, bladder, lung, thyroid, oral, tongue, esophageal, hepatocellular, pancreatic, and gastric carcinomas, etc.)[160,166,167,168,169,170] as well as sarcoma gastrointestinal stromal tumors [171]. Here, FASN is linked to cancer.